Literature DB >> 9631401

LGMD 2E in Tunisia is caused by a homozygous missense mutation in beta-sarcoglycan exon 3.

C G Bönnemann1, J Wong, C Ben Hamida, M B Hamida, F Hentati, L M Kunkel.   

Abstract

Four of the currently recognized autosomal recessive limb-girdle muscular dystrophies (LGMD type 2C-F) are caused by mutations in the genes encoding components of the sarcoglycan complex. LGMD 2C, caused by mutations in gamma-sarcoglycan, is prevalent in northern Africa, especially in Tunisia, where this type of muscular dystrophy was originally described. Although the disease initially was assumed to be genetically homogeneous in this region, linkage to the alpha-sarcoglycan locus (LGMD 2D) has also been found. We have now identified the first Tunisian family with beta-sarcoglycanopathy (LGMD 2E), further adding to the genetic heterogeneity of autosomal recessive LGMD in this population. Direct sequencing of the beta-sarcoglycan gene revealed a homozygous mutation (G272-->T, Arg91Leu) in exon 3. This change affects the same arginine residue in the immediate extracellular domain of the protein that was mutated to a proline (G272-->C, Arg91Pro) in a Brazilian family with a severe form of the disease. Immunohistochemical analysis for the sarcoglycan complex demonstrates absence of the known components of the complex in both of these families. We postulate that the immediate extracellular domain of beta-sarcoglycan may be important for the assembly and/or maintenance of this complex, potentially mediated by disulfide-bond formation to another sarcoglycan via the single cysteine residue in that domain.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9631401     DOI: 10.1016/s0960-8966(98)00014-5

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  8 in total

Review 1.  Finding the sweet spot: assembly and glycosylation of the dystrophin-associated glycoprotein complex.

Authors:  Dewayne Townsend
Journal:  Anat Rec (Hoboken)       Date:  2014-09       Impact factor: 2.064

2.  Disruption of heart sarcoglycan complex and severe cardiomyopathy caused by beta sarcoglycan mutations.

Authors:  R Barresi; C Di Blasi; T Negri; R Brugnoni; A Vitali; G Felisari; A Salandi; S Daniel; F Cornelio; L Morandi; M Mora
Journal:  J Med Genet       Date:  2000-02       Impact factor: 6.318

3.  Beta-sarcoglycanopathy.

Authors:  Seema Kapoor; Medha Tatke; Sandeep Aggarwal; Ashish Gupta
Journal:  Indian J Pediatr       Date:  2005-01       Impact factor: 1.967

Review 4.  Overview of the Muscle Cytoskeleton.

Authors:  Christine A Henderson; Christopher G Gomez; Stefanie M Novak; Lei Mi-Mi; Carol C Gregorio
Journal:  Compr Physiol       Date:  2017-06-18       Impact factor: 9.090

Review 5.  Neurogenomics in Africa: Perspectives, progress, possibilities and priorities.

Authors:  Rufus O Akinyemi; Mayowa O Owolabi; Tolulope Oyeniyi; Bruce Ovbiagele; Donna K Arnett; Hemant K Tiwari; Richard Walker; Adesola Ogunniyi; Raj N Kalaria
Journal:  J Neurol Sci       Date:  2016-05-06       Impact factor: 3.181

6.  Molecular organization of sarcoglycan complex in mouse myotubes in culture.

Authors:  Y M Chan; C G Bönnemann; H G Lidov; L M Kunkel
Journal:  J Cell Biol       Date:  1998-12-28       Impact factor: 10.539

7.  Genetics and genomic medicine in Tunisia.

Authors:  Houda Elloumi-Zghal; Habiba Chaabouni Bouhamed
Journal:  Mol Genet Genomic Med       Date:  2018-03       Impact factor: 2.183

8.  An AAV-SGCG Dose-Response Study in a γ-Sarcoglycanopathy Mouse Model in the Context of Mechanical Stress.

Authors:  David Israeli; Jérémie Cosette; Guillaume Corre; Fatima Amor; Jérôme Poupiot; Daniel Stockholm; Marie Montus; Bernard Gjata; Isabelle Richard
Journal:  Mol Ther Methods Clin Dev       Date:  2019-05-10       Impact factor: 6.698

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.